Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds

Journal of Medicinal Chemistry

Volumn 50, Issue 24, 2007, Pages 6024-6031

  Skinner Adams, Tina S ^a,b   Lowther, Jonathan ^c   Teuscher, Franka ^a   Stack, Colin M ^c   Grembecka, Jolanta ^d   Mucha, Artur ^e   Kafarski, Pawel ^e   Trenholme, Katharine R ^a   Dalton, John P ^c   Gardiner, Donald L ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^d UNIVERSITY OF VIRGINIA   (United States)

^e WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; BESTATIN; CHLOROQUINE; CYTOSOL AMINOPEPTIDASE; DIPEPTIDE DERIVATIVE; EXOPEPTIDASE; HEMOGLOBIN; LEUCINE; PHENYLALANINE; PHOSPHINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CLONE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; ENZYME ACTIVE SITE; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALARIA; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM CHABAUDI CHABAUDI; PLASMODIUM FALCIPARUM; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIMALARIALS; DIPEPTIDES; KINETICS; LEUCINE; LEUCYL AMINOPEPTIDASE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PHOSPHINIC ACIDS; PLASMODIUM CHABAUDI; PLASMODIUM FALCIPARUM; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 37849041347     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070733v     Document Type: Article

References (29)

1. Breman, J. G. The ears of the hippopotamus: Manifestations, determinants, and estimates of the malaria burden. Am. J. Trop. Med. Hyg. 2001, 64 (1-2 Suppl), 1-11.
2. Yamey, G. Roll Back Malaria: A failing global health campaign. BMJ [Br. Med. J.] 2004, 328 (7448), 1086-7.
3. Gardiner, D. L.; Trenholme, K. R.; Skinner-Adams, T. S.; Stack, C. M.; Dalton, J. P.; Overexpression, of leucyl aminopeptidase in Plasmodium falciparum parasites. Target for the antimalarial activity of bestatin. J. Biol. Chem. 2006, 281 (3), 1741-5.
4. Rosenthal, P. J. Hydrolysis of erythrocyte proteins by proteases of malaria parasites. Curr. Opin. Hematol. 2002, 9 (2), 140-5.
5. Stack, C. M.; Lowther, J.; Cunningham, E.; Donnelly, S.; Gardiner, D. L.; Trenholme, K. R.; Skinner-Adams, T. S.; Teuscher, F.; Grembecka, J.; Mucha, A.; Kafarski, P.; Lua, L.; Bell, A.; Dalton, J. P.; Characterization, of the Plasmodium falciparum M17 leucyl aminopeptidase. A protease involved in amino acid regulation with potential for antimalarial drug development. J. Biol. Chem. 2007, 282 (3), 2069-80.
6. Grembecka, J.; Mucha, A.; Cierpicki, T.; Kafarski, P. The most potent organophosphorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and activity. J. Med. Chem. 2003, 46 (13), 2641-55.
7. Duggleby, R. G.; Attwood, P. V.; Wallace, J. C.; Keech, D. B. Avidin is a slow-binding inhibitor of pyruvate carboxylase. Biochemistry 1982, 21 (14), 3364-70.
8. Burley, S. K.; David, P. R.; Sweet, R. M.; Taylor, A.; Lipscomb, W. N. Structure determination and refinement of bovine lens leucine aminopeptidase and its complex with bestatin. J. Mol. Biol. 1992, 224 (1), 113-40.
9. Kim, H.; Lipscomb, W. N. X-ray crystallographic determination of the structure of bovine lens leucine aminopeptidase complexed with amastatin: Formulation of a catalytic mechanism featuring a gem- diolate transition state. Biochemistry 1993, 32 (33), 8465-78.
10. Strater, N.; Lipscomb, W. N. Transition state analogue L-leucine-phosphonic acid bound to bovine lens leucine aminopeptidase: X-ray structure at 1.65 A resolution in a new crystal form. Biochemistry 1995, 34 (28), 9200-10.
11. Liu, J.; Istvan, E. S.; Gluzman, I. Y.; Gross, J.; Goldberg, D. E. Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems. Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (23), 8840-5.
12. Gavigan, C. S.; Dalton, J. P.; Bell, A. The role of aminopeptidases in haemoglobin degradation in Plasmodium falciparum-infected erythrocytes. Mol. Biochem. Parasitol. 2001, 117 (1), 37-48.
13. Scornik, O. A.; Botbol, V. Cellular uptake of 3H-bestatin in tissues of mice after its intravenous injection. Drug Metab. Dispos. 1997, 25 (7), 798-804.
14. Suda, H.; Aoyagi, T.; Takeuchi, T.; Umezawa, H. Inhibition of aminopeptidase B and leucine aminopeptidase by bestatin and its stereoisomer. Arch. Biochem. Biophys. 1976, 177 (1), 196-200.
15. Nwaka, S.; Hudson, A. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discovery 2006, 5 (11), 941-55.
16. Chen, X.; Chong, C. R.; Shi, L.; Yoshimoto, T.; Sullivan, D. J.; Jr.; Liu, J. O. Inhibitors of Plasmodium falciparum methionine aminopeptidase 1b possess antimalarial activity. Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (39), 14548-53.
17. Gavigan, C. S.; Machado, S. G.; Dalton, J. P.; Bell, A. Analysis of antimalarial synergy between bestatin and endoprotease inhibitors using statistical response-surface modelling. Antimicrob. Agents Chemother. 2001, 45 (11), 3175-81.
18. Skinner-Adams, T. S.; Andrews, K. T.; Melville, L.; McCarthy, J.; Gardiner, D. L. Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 2007, 51 (2), 759-62.
19. Sakakibara, T.; Ito, K.; Irie, Y.; Hagiwara, T.; Sakai, Y.; Hayashi, M1; Kishi, H.; Sakamoto, M.; Suzuki, M.; Irie, Y.; et al. Toxicological, studies on bestatin. I. Acute toxicity test in mice, rats and dogs. Jpn. J. Antibiot. 1983, 36 (11), 2971-84.
20. Scornik, O. A.; Botbol, V. Bestatin as an experimental tool in mammals. Curr. Drug Metab. 2001, 2 (1), 67-85.
21. Ichinose, Y.; Genka, K.; Koike, T.; Kato, H.; Watanabe, Y.; Mori, T.; Iioka, S.; Sakuma, A.; Ohta, M., Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. J. Natl. Cancer Inst. 2003, 95 (8), 605-10.
22. Mucha, A.; Pawel, M.; Hurek, J.; Kafarski, P. Synthesis and activity of phosphinic tripeptide inhibitors of cathepsin C. Bioorg. Med. Chem. Lett. 2004, 14 (12), 3113-6.
23. Dixon, M. The determination of enzyme inhibitor constants. Biochem. J. 1953, 55 (1), 170-1.
24. Morrison, J. F.; Walsh, C. T. The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. Relat. Areas Mol. Biol. 1988, 61, 201-301.
25. Sali, A.; Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993, 234 (3), 779-815.
26. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 2006, 49 (21), 6177-96.
27. Trager, W.; Jensen, J. B. Human malaria parasites in continuous culture. Science 1976, 193 (4254), 673-5.
28. Geary, T. G.; Divo, A. A.; Jensen, J. B. An in vitro assay system for the identification of potential antimalarial drugs. J. Parasitol. 1983, 69 (3), 577-83.
29. Huber, W.; Koella, J. C. A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites. Acta Trop. 1993, 55 (4), 257-61.